Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting
December 01 2021 - 8:30AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) therapies for cancer, today announced that
management will host a conference call to review data to be
presented at the American Society of Hematology Annual Meeting from
the ALPHA and ALPHA2 Phase 1 trials in relapsed/refractory
non-Hodgkin lymphoma and the UNIVERSAL Phase 1 trial in
relapsed/refractory multiple myeloma on December 13, 2021 at 1:30
PM Pacific Time/4:30 PM Eastern Time.
Conference Call and Webcast DetailsTo access
the live conference call by telephone, please dial 1 (866) 940-5062
(U.S.) or 1 (409) 216-0618 (International). The conference ID
number for the live call is 1281484. The webcast will be made
available on the Company's website at www.allogene.com under the
Investors tab in the News and Events section. Following the live
audio webcast, a replay will be available on the Company's website
for approximately 30 days.
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies
for cancer. Led by a management team with significant experience in
cell therapy, Allogene is developing a pipeline of “off-the-shelf”
CAR T cell therapy candidates with the goal of delivering readily
available cell therapy on-demand, more reliably, and at greater
scale to more patients. For more information, please visit
www.allogene.com, and follow @AllogeneTx on Twitter and
LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The press release may, in some cases, use terms
such as "predicts," "believes," "potential," "proposed,"
"continue," "estimates," "anticipates," "expects," "plans,"
"intends," "may," "could," "might," "will," "should" or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. Forward-looking statements
include statements regarding intentions, beliefs, projections,
outlook, analyses or current expectations concerning, among other
things: the ability to develop AlloCAR T therapies for cancer and
the potential benefits of AlloCAR T therapy. Various factors may
cause differences between Allogene’s expectations and actual
results as discussed in greater detail in Allogene’s filings with
the Securities and Exchange Commission (SEC), including without
limitation in its Quarterly Report on Form 10-Q for the quarter
ended September 30, 2021. Any forward-looking statements that are
made in this press release speak only as of the date of this press
release. Allogene assumes no obligation to update the
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Sep 2023 to Sep 2024